Rafael Pharmaceuticals Joins the Pancreatic Cancer Action Network’s Scientific & Medical Affairs Industry Membership
07 nov. 2019 09h00 HE
|
Rafael Pharmaceuticals, Inc.
Cranbury, NJ, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that...
Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update
30 oct. 2019 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
- Management to host webcast and conference call on Wednesday, November 6, 2019 at 5 p.m. ET / 2 p.m. PT - HOUSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM),...
PharmaCyte Biotech to Change Future of Treating Diseases with Validation of Encapsulation Technology in Pancreatic Cancer Trial
28 oct. 2019 09h00 HE
|
PharmaCyte Biotech
NEW YORK, NY, Oct. 28, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has a technology that could very well change the way a host of hard-to-treat diseases are treated for the foreseeable...
Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial of CPI-613® (devimistat) in Patients with Metastatic Pancreatic Cancer
24 oct. 2019 09h00 HE
|
Rafael Pharmaceuticals, Inc.
Cranbury, NJ, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...
FibroGen Announces First Patient Dosed in LAPIS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients With Locally Advanced Pancreatic Cancer
23 oct. 2019 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, Oct. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced the dosing of the first patient in the LAPIS Phase 3 clinical study of pamrevlumab in patients with...
PharmaCyte Biotech Closer to Submitting IND with Successful Completion of Clinical Trial Product
16 oct. 2019 09h00 HE
|
PharmaCyte Biotech
NEW YORK, NY, Oct. 16, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has now moved one step closer to submitting an Investigational New Drug application (IND) to the U.S. Food and Drug...
Rafael Pharmaceuticals Reaches Milestone of 100 Patients Enrolled in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer
08 oct. 2019 09h00 HE
|
Rafael Pharmaceutical Inc.
Cranbury, NJ, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...
PharmaCyte Biotech's Pancreatic Cancer Therapy Production in Final Days of Key Manufacturing Run
23 sept. 2019 09h00 HE
|
PharmaCyte Biotech
NEW YORK, NY, Sept. 23, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) and its partner, Austrianova, along with the company’s cellular biologist, David Judd, are all more confident than...
DrugCendR Inc. Announces the Appointment of Dr. Daniel Von Hoff as Clinical Advisor
20 août 2019 13h17 HE
|
DrugCendR Inc.
LA JOLLA, Calif., Aug. 20, 2019 (GLOBE NEWSWIRE) -- DrugCendR, Inc., a clinical-stage biotech company developing next generation therapies for the treatment of solid tumors, today announced that Dr....
AB Science fait le point sur le programme clinique du masitinib
05 août 2019 01h31 HE
|
AB Science
Paris, 5 août 2019, 7h30 Point sur le programme clinique du masitinib AB Science SA (NYSE Euronext - FR0010557264 - AB) fait le point sur le programme clinique du masitinib. Les points...